• Article  

      Rituximab in combination with CNOP chemotherapy in patients withn previously untreated indolent non-Hodgkin's lymphoma 

      Economopoulos, T.; Fountzilas, George; Pavlidis, Nicholas; Kalantzis, Dimitrios; Papageorgiou, E.; Christodoulou, C.; Hamilos, G.; Nikolaides, C.; Dimopoulos, M. A. (2003)
      Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy. The purpose ...
    • Article  

      Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP 

      Economopoulos, T.; Dimopoulos, M. A.; Mellou, S.; Pavlidis, Nicholas; Samantas, E.; Nikolaides, C.; Tsatalas, C.; Papadopoulos, A.; Papageorgiou, E.; Papasavvas, P.; Fountzilas, George (2002)
      Introduction: During the last few years epirubicin (E) and mitoxantrone (M) (Novantrone) have been used in the treatment of non-Hodgkin's lymphoma (NHL), because of their favorable principal profile. In particular, M has ...